New score predicts risk of postoperative liver failure with high accuracy

Surgical removal of parts of the liver remains the only curative approach for patients with liver-specific cancer.

A rare disease first; Lilly’s Alzheimer’s push; Argenx’s next act; Novartis’ obesity approach; and more

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 21, 2024

Pharmalittle: We’re reading about a Vertex pain drug, the Feds suing CVS over opioids, and more

Top of the morning to you, and a fine one it is. Clear blue skies and chilly breezes are wafting across the Pharmalot campus, where

December 19, 2024

Lonza’s modest forecast for cell and gene therapies points to uncertainty about sector’s future

As Lonza unveiled its four-year financial predictions on Tuesday, observers were left unsure about the CDMO’s cell and gene therapy (CGT) forecast. Nonetheless, they were

October 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.